MoonLake Immunotherapeutics
MLTXDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
Sonelokimab
Hidradenitis Suppurativa
Risankizumab
Arthritis, Psoriatic
Sonelokimab (M1095)
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sonelokimab | Phase 3 | Hidradenitis Suppurativa | - | - |
Risankizumab | Phase 3 | Arthritis, Psoriatic | - | - |
Sonelokimab (M1095) | Phase 2 | Hidradenitis Suppurativa | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MoonLake Immunotherapeutics's drug pipeline?→
CatalystAlert tracks 3 drug candidates in MoonLake Immunotherapeutics's (MLTX) pipeline across Phase 3, Phase 2. Its lead program is Sonelokimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MoonLake Immunotherapeutics's next FDA catalyst?→
MoonLake Immunotherapeutics's (MLTX) next tracked catalyst is a Phase 3 expected September 28, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MLTX biotech catalysts?→
Add MLTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MoonLake Immunotherapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.